ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 24262
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 24262

A Phase 2 Study of Relacorilant in Combination with Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)(CORT125134-557)

 

Disease Types: GYN Cancer Research

Eligibility Requirements:

• Histologically confirmed high-grade serous or endometrioid OC/FP/PPC
• Mixed histology of high grade serous and endometrioid are permitted
• Mixed tumors including other histologies are excluded
• Platinum-resistant disease
• Primary plt-refractory disease excluded
• 1-3 prior lines of systemic tx for ovarian cancer
• At least 1 prior line of plt-based therapy required
• Pts with documented BRCA1/2 mutation should have received PARPi
• Hormonal tx are not counted as separate therapies
• Pts may have received prior tx with bevacizumab
• Pts who progressed while receiving weekly paclitaxel or nap-paclitaxel in
PROC setting are excluded
• Concurrent tx with mifepristone or other GR modulators excluded
• Measurable disease by RECIST v1.1

For more information on this trial CLICK HERE .

Available at:

Virginia Oncology Associates